MEPSGEN Joins BIO USA 2025 to Expand Global Partnerships

2025-06-10

MEPSGEN partners with Cleveland Clinic to advance human gut-on-a-chip research

2025-05-28

Introducing the Next Generation of MPS Technology by MEPSGEN

2025-05-22

MEPSGEN Signs Research Agreement with KAIST Team to Develop Retinal Vascular Barrier Model

2025-05-15

[Interview] MEPSGEN's CEO warns of overlooked RNA damage risk during LNP manufacturing

2025-05-02

MEPSGEN Presents Advanced Nanoparticle Technology at LNP Summit in Boston

2025-04-17

MEPSGEN Unveils 'NanoCalibur GMP' for Preclinical and Clinical Nanoparticle Production

2025-03-13

MEPSGEN Collaborates with University of Utah for Corneal Model Research

2025-03-05

MEPSGEN and AIGEN Science Sign MOU to Advance Innovative Drug Development

2025-02-07

MEPSGEN appoints renowned MPS expert as new Chief Scientific Officer

2025-01-22

MEPSGEN CEO YongTae Kim says organ-on-chips will change the clinical paradigm by overcoming the limitations of animal testing.

2025-01-08

Mepsgen raises $14.9 million in series C funding, expands global reach

2024-11-19

NanoCalibur™ to Lead Innovation in Nanomedicine, CEO YongTae Kim Says

2024-10-24

Mepsgen launches automated nanoparticle production equipment ‘NanoCalibur’

2024-10-22

MEPSGEN Receives ￦5.6 Billion Research Grant from MOTIE

2024-08-06

Modeling of Human Organ Tissue Barrier on Organ-on-a-Chip

2024-07-22

MEPSGEN showcases ProMEPS, NanoCalibur at BIO International Convention 2024

2024-06-03

MEPSGEN showcases ProMEPS™ at BIO KOREA 2024

2024-05-02

MEPSGEN Attends 2024 HANKYUNG BIO INSIGHT FORUM

2024-03-11

MEPSGEN Attends 2024 JPMHC

2024-01-12